Join the Opdivo group to help and get support from people like you.
Opdivo News
U.S. Food and Drug Administration Approves Opdivo (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) Mar 07, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab), in combination with ...
Injected Opdivo for Kidney Cancer Works Equally Well as IV Form: Study
TUESDAY, Jan. 30, 2024 – Opdivo, one of the new generation of immunotherapy cancer treatments, appears to help kidney cancer patients equally well when given as a quick injection versus the current...
Immunotherapy's Benefits for Colon Cancer Survivors Continue Long After Treatment Stops
WEDNESDAY, Dec. 20, 2023 – Many patients with advanced colon cancers who are successfully treated with immunotherapy and then stop those treatments appear to face little risk of tumor progression...
FDA Approves Nivolumab as Adjuvant Treatment for Melanoma
WEDNESDAY, Oct. 18, 2023 – The U.S. Food and Drug Administration has approved Opdivo (nivolumab) for the adjuvant treatment of completely resected stage IIB/C melanoma in patients ages 12 years and...
U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant improvement in recurrence-free survival compared to placebo1 CheckMate -76K marks the fifth Opdivo-based...
Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
WEDNESDAY, Oct. 4, 2023 – For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published...
Immune Checkpoint Inhibitors Can Be Active in Penile Cancer
WEDNESDAY, Aug. 23, 2023 – Immune checkpoint inhibitors (ICIs) are active in some patients with penile cancer (PeCa), according to a study published online Aug. 11 in the Journal of the National...
Nivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma
WEDNESDAY, Aug. 23, 2023 – For patients with metastatic melanoma who receive frontline anti-programmed death protein 1 (PD-1) or therapy against programmed cell death 1 ligand 1 and whose tumors...
T-Cell Tolerant Fraction Can Predict Immunotherapy Toxicity
MONDAY, Aug. 21, 2023 – The T-cell tolerant fraction predicts clinically significant immune-related adverse events (irAEs) among patients with cancer treated with immune checkpoint inhibitors...
A New Treatment Option for a Form of Sudden Hair Loss
THURSDAY, Aug. 17, 2023 – A new type of medication, JAK inhibitors, can effectively treat moderate to severe alopecia areata, a hair loss condition that has been historically hard to treat. A study...
Immune-Based Cancer Drugs Offer Hope Against Penile Cancers
TUESDAY, Aug. 15, 2023 – Men who have a rare cancer of the penis may have a new treatment option, according to researchers who found promise in immunotherapy. This new study focused on cancer that...
Pharmacy-Level Stewardship Can Save on Immune Checkpoint Inhibitors
TUESDAY, July 11, 2023 – Adoption of pharmacy-level stewardship strategies for immune checkpoint inhibitors could generate sizable reductions in spending for these drugs, according to a study...
Determinants of Overall Survival in Metastatic Uveal Melanoma Identified
WEDNESDAY, July 12, 2023 – Factors associated with improved survival in metastatic uveal melanoma include female sex and use of anti‐cytotoxic T lymphocyte-associated antigen (CTLA)‐4 and ant...
Could Loss of the Y Chromosome Help Speed Cancers in Men?
WEDNESDAY, June 21, 2023 – It’s common knowledge that loss is a part of male aging — loss of hair, loss of muscle tone, loss of vision or hearing. But men growing older also start losing the very thi...
2 Years of Immunotherapy for Advanced Lung Cancer Might Be Enough: Study
FRIDAY, June 9, 2023 – For patients battling late-stage lung cancer, prospects for survival have improved significantly since the advent of medications known as immune checkpoint inhibitors. But...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Colorectal Cancer, Hepatocellular Carcinoma, Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma